Abstract
Racial health disparities are a pervasive problem in the United States. While these disparities are mainly due to structural racism, genomicists have been attempting to find a genetic cause to these largely social problems. Disparities in disease rate and outcomes for asthma and diabetes present opportunities for analyzing the different techniques embodied by genomicists and population health experts. In this paper, I carve out a middle path between genomicists and their critics, highlighting drug disparities, a small subset of larger racial disparities, which might be targeted through pharmacogenomics.
